You are here

Verzenio

FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands

FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands

Fierce Pharma

Flag link:

As Lilly gears up for key 2022 launches, Trulicity, Taltz and more drive solid growth

As Lilly gears up for key 2022 launches, Trulicity, Taltz and more drive solid growth

Fierce Pharma

Flag link:

Eli Lilly's Verzenio snags first-in-class FDA approval for early breast cancer. But limited label poses a challenge

Eli Lilly's Verzenio snags first-in-class FDA approval for early breast cancer. But limited label poses a challenge

Fierce Pharma

early breast cancer

Flag link:

Lilly warms up for Olympics with Team USA athletes in ads for Trulicity, Emgality and Verzenio

Lilly warms up for Olympics with Team USA athletes in ads for Trulicity, Emgality and Verzenio

Fierce Pharma

pharma marketing

Flag link:

Look for Eli Lilly's Verzenio to hit $4.6B, thanks to early breast cancer win: analyst

Look for Eli Lilly's Verzenio to hit $4.6B, thanks to early breast cancer win: analyst

Fierce Pharma

early breast cancer

Flag link:

Ibrance trial failure dashes Pfizer’s growth hopes for the drug

Ibrance trial failure dashes Pfizer’s growth hopes for the drug

Pharmaforum

Flag link:

ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer

ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer

Fierce Pharma

Flag link:

Eli Lilly Shares Surge After Successful 'Verzenio' Breast Cancer Drug Trial

Eli Lilly Shares Surge After Successful 'Verzenio' Breast Cancer Drug Trial

TheStreet.com

clinical trials

Flag link:

Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation

Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation

RAPS.org

Flag link:

Lilly cancer push boosted by survival benefit to key drug

Lilly cancer push boosted by survival benefit to key drug

Biopharma Dive

metastatic breast cancer

clinical trials

Flag link:

Lilly price break reverses NICE’s 'No' ruling on breast cancer drug Verzenio

Lilly price break reverses NICE’s 'No' ruling on breast cancer drug Verzenio

Fierce Pharma

Flag link:

NICE spurns Lilly’s breast cancer drug Verzenio in favor of rivals from Pfizer and Novartisspir

NICE spurns Lilly’s breast cancer drug Verzenio in favor of rivals from Pfizer and Novartisspir

Fierce Pharma

Flag link:

Lilly’s breast cancer drug Verzenio approved in EU

Lilly’s breast cancer drug Verzenio approved in EU

Pharmaforum

Flag link:

Large and Small: Here’s What’s Moving Eli Lilly and Zosano

Large and Small: Here’s What’s Moving Eli Lilly and Zosano

Yahoo/Market Exclusive

advanced breast cancer

Flag link:

AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio

AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio

Yahoo/Zacks.com

Flag link:

Latecomer Verzenio stands out from Ibrance, Kisqali in launch's early days: Lilly

Latecomer Verzenio stands out from Ibrance, Kisqali in launch's early days: Lilly

Fierce Pharma

breast cancer. Eli Lilly

Flag link:

Lilly's lung cancer drug fails main goal of key study

Lilly's lung cancer drug fails main goal of key study

Yahoo/Reuters

clinical trials

non-small cell lung cancer

Flag link:

Lilly steps up to rival Pfizer, Novartis with Verzenio breast cancer approval

Lilly steps up to rival Pfizer, Novartis with Verzenio breast cancer approval

Fierce Pharma

Flag link: